Table 2. Impact of Virological and Epidemiological Features on Virologic Response During Therapy.
| Data | RVR (n = 21) | EVR (n = 20) | Non-EVR (n = 9) | P value |
|---|---|---|---|---|
| HCV Viral Loada, Mean ± SD, IU/mL | 5.00×105± 8.36×105 | 1.27×106± 1.09×106 | 1.09×106± 0.48×106 | 0.02b |
| Genotype (%) | 0.17 | |||
| 1a | 10 (31.2) | 15 (46.9) | 7 (21.9) | |
| 3a | 10 (58.8) | 5 (29.4) | 2 (11.8) | |
| Duration of HCV Infectionc, Mean ± SD, y | 4.90 ± 4.34 | 5.91 ± 3.74 | 9.37 ± 4.95 | 0.04b |
| HBV-DNA | 0.04b | |||
| HBV-DNA positive (%)d | 9 (50) | 9 (50) | 0 (0.0) | |
| HBV-DNA negative (%)e | 12 (37.5) | 11(34.4) | 9 (28.1) |
aHCV viral load are baseline values
bStatistically significant
cDefined between the first times of diagnosis of HCV infection and beginning therapy in our study
dTotal response rate (RVR + EVR) in cases with positive results for HBV-DNA was 100 %
eTotal response rate in (RVR + EVR) cases with negative results for HBV-DNA was 71.5 %